An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Odomzo

Chemical Namesonidegib
Dosage FormCapsule (oral; 200 mg)
Drug ClassInhibitors
SystemSkin
CompanySun Pharma Global
Approval Year2015

Indication

  • To treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy.
Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Odomzo (sonidegib) Prescribing Information2019Sun Pharmaceutical Industries, Inc., Cranbury, NJ
Document TitleYearSource
Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis2018Journal of the American Academy of Dermatology
Document TitleYearSource
Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines2019European Journal of Cancer